# Relative Bioavailability of Evobrutinib Tablet Batches

> **NCT07214922** · PHASE1 · COMPLETED · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 28 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Treatment A
- **DRUG:** Treatment B
- **DRUG:** Treatment C
- **DRUG:** Treatment D

## Key facts

- **NCT ID:** NCT07214922
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-18
- **Primary completion:** 2023-02-24
- **Final completion:** 2023-02-24
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07214922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07214922, "Relative Bioavailability of Evobrutinib Tablet Batches". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07214922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*